Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Public ClinicalTrials.gov record NCT00917384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Study identification
- NCT ID
- NCT00917384
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 355 participants
Conditions and interventions
Conditions
Interventions
- ramucirumab Biological
- Placebo Drug
- Best Supportive Care (BSC) Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Jun 30, 2012
- Completion
- Nov 30, 2015
- Last update posted
- Sep 24, 2019
2009 – 2015
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Bakersfield | California | 93309 | — |
| ImClone Investigational Site | La Jolla | California | 92093 | — |
| ImClone Investigational Site | Redlands | California | 92374 | — |
| ImClone Investigational Site | Chicago | Illinois | 60612 | — |
| ImClone Investigational Site | New Orleans | Louisiana | 70112 | — |
| ImClone Investigational Site | Boston | Massachusetts | 02115 | — |
| ImClone Investigational Site | Omaha | Nebraska | 68114 | — |
| ImClone Investigational Site | New York | New York | 10003 | — |
| ImClone Investigational Site | West Reading | Pennsylvania | 19611 | — |
| ImClone Investigational Site | Providence | Rhode Island | 02903 | — |
| ImClone Investigational Site | Charleston | South Carolina | 29425 | — |
| ImClone Investigational Site | Knoxville | Tennessee | 37920 | — |
| ImClone Investigational Site | Memphis | Tennessee | 38119 | — |
| ImClone Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00917384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2019 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00917384 live on ClinicalTrials.gov.